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Summary
Aims. About 60% of the oral cancer arise on a
pre-existent potentially malignant disorder of oral
mucosa like the oral proliferative verrucous
leukoplakia. The treatment with the photodynamic
therapy of these lesions represents, in the last
years, an innovative, non-invasive and effective
therapeutic possibility to achieve the secondary
prevention of oral cancer. In the last decade, case
reports have described patients with similar treat-
ed through a photochemical reaction induced by
laser light. The aim of this study is to evaluate the
effectiveness of the topical 5-ALA photodynamic
therapy in the treatment of a case of Oral prolifer-
ative verrucous leukoplakia.
Case report. A female patient of 80 years old af-
fected by white verrucous plaques on the right
buccal mucosa was recruited for our case report.
The right side lesion was treated with the photo-
dynamic therapy with topical administered 5-
aminolevulinic acid using the 635 nm laser light
to activate the photosensitizer.
Results. The lesion showed complete response
after 4 sessions of photodynamic therapy and no
recurrence was noticed after 12 months. 
Conclusions. The photodynamic therapy can be
considered an effective treatment in the manage-
ment of oral verrucous proliferative leukoplakia,
but more clinical trials, with prolonged follow-up
controls, are necessary to evaluate its effective-
ness in the mid and long time period.
Key words: photodynamic therapy, oral leuko-
plakia, oral cancer, 5-aminolevulinic acid, poten-
tially malignant disorders.
Introduction
Oral squamous cell carcinoma (OSCC) is the fifth
common cancer in the world with an annual world-
wide incidence exceeding 300,000 cases (1). The
disease is an important cause of death and morbidity,
with a 5-year survival less than 50% (2). These poor
data are mainly due to the frequent great diagnostic
delay that characterizes the early phases of OSCC
cases. So the prevention of OSCC is the most impor-
tant approach to minimize its incidence and to pro-
vide a better quality of life of patients. In particular,
the secondary prevention is based on the early diag-
nosis and management of the so-called Potentially
Malignant Disorders (PMDs), a series of pathologies
characterized by the risk of neoplastic degeneration
(2). Among the PMDs of the oral mucosa the most
frequent is the Oral Leukoplakia (OL) (2). Clinically,
OLs can be classified in two different groups: homo-
geneous and non-homogeneous lesions. Moreover,
another type of OL characterized by a multifocal lo-
calization and a very high risk of malignant transfor-
mation (about 70%) is the oral proliferative verrucous
leukoplakia (OPVL) (3,4). The OPVL is more common
in middle-aged women and the female-to-male ratio
is 4:1 (5); is of uncertain etiology and is not strongly
associated with tobacco use or alcohol with the HPV
infection that may play an important role in these le-
sions (5). Multiple oral sites may be involved and be-
fore malignant transformations can pass many years
up to even some decades (4).
In the last decades many treatments were used in the
treatment of PMDs: traditional surgery (6), electro-
surgery, cryosurgery, laser surgery and the adminis-
tration of drugs (e.g. carotenoids, exc.) (7). Recently
the progresses in the knowledge suggested the pos-
sibilities of a non invasive treatment of OL with the
laser (8). Generally the laser interaction on oral mu-
cosa is based on the phototermic effect, that means
to have the possibility to cut the tissue to perform a
biopsy (9,10). Another effect of laser on soft tissue is
a photochemical effect, the so called photodynamic
therapy (PDT) that is based upon a photochemical
laser light induced reaction, strictly directed on patho-
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logic cells, permitting a safe and complete removal of
the lesion without sacrifice of healthy tissue (11). The
PDT involves three components: light, a photosensi-
tizer and oxygen. A photosensitizer, or its metabolic
precursor, is locally applied upon the lesion. The acti-
vation of the photosensitizer with a low level laser
light, determines the transition of the agent from a
low energy ground state to an excited singlet state.
The singlet state can react with endogenous oxygen
to produce singlet oxygen and other reactive oxigen
species (ROS), causing a rapid and selective de-
struction of the target tissue (Fig. 1).
These photochemical induced reactions lead in many
ways to the destruction of neoplastic tissues; as a
first, ROS kill directly tumor cells; in other cases, PDT
damages the tumor associated vascular tissues,
leading to thrombus formation and subsequent tumor
infarction. Moreover PDT can also elicit an immune
response against tumor cells (12). The advantages of
the PDT in the treatment of OL were confirmed in
many studies in literature (8, 12-14). On the other
hand, PDT in several cases, requires multiple ses-
sions of irradiation to achieve complete regression of
the lesion and the costs of the laser and of the photo-
sensitizers are high.
A lot of natural and synthetic agents have photosensi-
tizing potential, but the 5-aminolevulinic acid (5-ALA)
is one of the most important photosensitizer in the
management of OL. For the treatment of pre-malig-
nant and malignant lesions in the oral cavity has been
used PDT with topical administered 5-ALA. Due to
the limited depth of topical 5-ALA administration, and
the limited light penetration of 635 nm laser light, the
use of 5-ALA is restricted to superficial lesions (1-2
mm) such as homogeneous flat leukoplakia, ery-
troleukoplakia and verrucous leukoplakia (15). 5-ALA
is rapidly cleared from the tissue and the body within
48 hours and skin photosensitivity lasts less than 24
hours (15). The aim of this study is to report the man-
agement of a clinical case of OVPL trough the PDT
obtained with the locally administration of a 20% gel
of 5-ALA. 
Case report
A female patient of 80 years was recruited for the
study; history and general physical investigation re-
vealed no relevant findings and no tobacco-chewing
or smoking habit was reported from the patient. The
clinical examination of the mouth revealed painless
white verrucous plaque lesion with multiple peaks on
the buccal mucosa bilaterally (Fig. 1). A clinical provi-
sional diagnosis of OVPL was made considering the
multifocal, verrucous aspect of the lesion (16) and,
subsequently, this diagnosis was confirmed by inci-
sional biopsy of the diseased mucosa. The histologi-
cal examination revealed proliferative corrugated hy-
perkeratosis, acanthosis, mitoses, broad rete ridges
and inflammatory cell infiltrated on the connective tis-
sue. The lesion was photographed for further evalua-
tion. Considering the dimension of the lesion, we de-
cided to treat the lesion with a minimal invasive tech-
nique: the topical 5-ALA-PDT. The consensus for the
treatment from the patient was required before the
start of the therapy.
The formulation of 20% gel of 5-ALA used in our
study was prepared using 25% of Lutrol F127 (Basf
Chemtrade GmbH, Burgbernheim, Deutschland) and
1% of Carbopol 971P (Lubrizol, Cleveland-Ohio
State, USA). Double concentrated gels of Lutrol F127
and Carbopol 971P in water were separately pre-
pared prior to mixing. After refrigerating at 4° C, the
solution of Lutrol F127 was mixed with equal volume
of the Carbopol 971P gel and the mixture was stored
at 4° C. Prior to use, 800 mg of gel was mixed with
200 mg of 5-ALA (Fagron GmbH, Barsbuttel,
Deutschland). The formulation was used within 3
hours after the preparation. A thin layer of gel was
applied topically on the lesion using a microbrush
(Fig. 2). For the first 10 minutes after the application
of the gel, three cotton rolls were placed onto the ori-
fices of majors salivary glands to avoid the dilution of
gel by the saliva. In addition, during this period, the
doctor controlled the salivary flow by intermittent suc-
tion. The gel was left 1.5 hours over the lesion to per-
mits its gathering into target cells. During this period,
a gauze was placed over the lesion to avoid the re-
moval of gel. For the activation of the photosensitizer
Figure 1. Clinical aspect of the lesion before 5-ALA-PDT
treatment.
Figure 2. Application of 20% 5-ALA gel on the lesion.
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was used a diode laser of 635nm (Doctor Smile-Den-
tal Laser, Vicenza, Italy) (Fig. 3). Each application
consisted of five 3 mins and one 100s irradiations
with five 3-minutes breaks for a total of 1000s (flu-
ence rate: 100mW/cm2, total energy dose 100J/cm2)
using the fractionated protocol of irradiation de-
scribed by Chen et al. (14). With this irradiation proto-
col, the lesional epithelial cells have the possibility to
regenerate new PpIX and obtain new oxygen during
multiple 3-minutes resting period. The laser has been
set at a very low power (100mW), to take advantage
only of the photochemical effect of the laser, without
the overheating of the targeted tissues. The treatment
was performed twice a week until the clinical resolu-
tion of the lesion. At the end of the therapy, the pa-
tient was arranged for a follow-up schedule once a
month and clinical photographs were taken at each
patient’s visit to evaluate the clinical outcome of PDT. 
The lesion showed complete response after 4 treat-
ments of PDT (Fig. 4). The treatment was painless
and the patient did not require either local anesthesia
during the irradiation or analgesics drugs after the
treatment. The examination at 6 months after the last
session of PDT showed that the OPVL disappeared
completely with a good healing of the mucosa. The
patient was satisfactory for the treatment and the fol-
low-up at 12 months showed no recurrence (Fig. 5).
Discussion
In our case the results are encouraging. The suc-
cessful clinical outcome could be due to the gel
preparation, the fractionated protocol of irradiation
used, and the characteristics morphological, histolog-
ic and biological features of the lesion. The 20% 5-
ALA gel was adherent to oral mucosa and partially re-
sistant to the dilution of saliva. This aspect is very im-
portant because the gel form helped the absorption of
5-ALA from the mucosal surface. The fractionated
protocol of irradiation allows the regeneration of new
PpIX by the lesional epithelial cells and the obtaining
of new oxygen during multiple 3-minutes rests. So re-
sults in a more successful clinical outcome for the
therapy of OVPL. Moreover the verrucous appear-
ance of this lesion provided a large area of retention
for the gel, resulting in a difficult removal of 5-ALA
from salivary flow. 
One of the main limitation of the 5-ALA-PDT is the
low depth of penetration of the topical photosensitiz-
er. For this reason, this therapy is restricted to super-
ficial lesions of 1-2 mm of thickness.
Previous study demonstrated the effectiveness of
this therapy in the management of OL. Fan et al.
(13) treated 12 patients with oral dysplastic lesions
using orally administered ALA. All 12 patients
showed regression of the lesion of the lesions to
normal or less dysplastic. Kübler et al. (13) treated
12 patients affected by leukoplakia of the oral mu-
cosa for several years. 20% ALA cream was applied
to the lesion for 2 hours. Five patients showed com-
plete response, four patients showed a partial reso-
ponse, and in three patients treatment showed no
response. Sieron et al. (14) treated 12 patients with
lesions that affected a variety of intraoral sites using
10% ALA cream. Irradiation was performed in 6-8
sessions of therapy. A complete response was ob-
tained in 10 patients, with one recurrence during 6
months. The potential advantages of the PDT for
treating the OPVL are: moderate side-effects, possi-
bility to give repeated doses without cumulative tox-
ic effects, excellent aesthetic results with healing
process characterized by little or no scars and re-
Figure 3. Irradiation with 635 nm diode laser.
Figure 5. Clinical aspect after 12 months of follow-up.
Figure 4. Clinical resolution after 4 treatments of 5-ALA-
PDT.
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duction of pain during the treatment. The poor side
effects and the lack of invasiveness permit the repe-
tition of the treatment in case of recurrences even in
the short period. The disadvantages of the PDT con-
sist mainly in its high costs and the longer duration,
up to five weeks. 
Conclusions
In this case report, 5-ALA-PDT has been an effective
and non-invasive treatment for the management of
the OVPL. It has been easily accepted by the pa-
tient. The main problem of this therapy is the difficul-
ty to avoid the removal of gel by salivary flow. The
development of gel or other vehicles more adhesive
to oral mucosa may enhance the absorption of the
photosensitizer increasing the success of clinical
outcome of PDT. In spite of the encouraging results
of our study, more clinical trials with prolonged fol-
low-up controls are necessary to evaluate the real
absolute effectiveness of this therapy in the mid and
long time.
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